SCHEMBL1722406

SCHEMBL1722406

Cn1cnc(S(=O)(=O)N(Cc2ccccc2)c2ccc(C(=O)N3CCN(c4ccccc4)CC3)cc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
HTT P42858 2/20 0.58
KMT2A Q03164 3/20 0.52
HPGD P15428 2/20 0.52
GAA P10253 2/20 0.51
MEN1 O00255 2/20 0.50
POLB P06746 2/20 0.47
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
FNTA P49354 1/20 0.45
FNTB P49356 1/20 0.45
SLC6A7 Q99884 1/20 0.44
MAPK1 P28482 1/20 0.44
TP53 P04637 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1723243 0.95 LMNA (0.54) LMNASMN1; SMN2HTTKMT2AHPGD
SCHEMBL303115 0.93 LMNA (0.52) LMNASMN1; SMN2HTTKMT2AHPGD
SCHEMBL1725046 0.92 LMNA (0.54) LMNASMN1; SMN2HTTKMT2AHPGD
SCHEMBL303692 0.92 LMNA (0.66) LMNASMN1; SMN2HTTKMT2AHPGD
SCHEMBL1725647 0.90 LMNA (0.53) LMNASMN1; SMN2HTTKMT2AGAA
SCHEMBL3275527 0.89 LMNA (0.51) LMNASMN1; SMN2HTTKMT2AHPGD
SCHEMBL302045 0.87 SLC6A7 (0.53) LMNASMN1; SMN2HTTKMT2AHPGD
SCHEMBL306227 0.87 TSHR (0.49) LMNASMN1; SMN2HTTKMT2AGAA
SCHEMBL3274787 0.86 LMNA (0.52) LMNASMN1; SMN2HTTKMT2AHPGD
SCHEMBL1722793 0.86 LMNA (0.47) LMNASMN1; SMN2HTTKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 LMNA 1683/4885SMN1; SMN2 3175/4885HTT 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.